S&P 500 Industrials Sector SEC Filings — March 17, 2026

17-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) issued a press release on March 17, 2026, announcing that its RAD division received an order for 10 RIO Mini units with SARA licenses from a major Midwest construction company. No financial terms or order value were disclosed.

• ·Filing includes Exhibit 99.1: Press release dated March 17, 2026.

17-03-2026

Mechanics Bancorp reported net income of $266M in 2025, up 817% YoY from $29M, boosted by a $145M bargain purchase gain from the September 2, 2025 merger with HomeStreet Bank and noninterest income swing to $223M from a $139M loss. Net interest income grew 13% YoY to $586M with NIM expanding 12 bps to 3.43%, while total assets expanded 36% to $22.4B and deposits rose 36% to $19.0B. However, provision for credit losses on loans increased to $20.5M from a $1.6M reversal, nonaccrual loans tripled to $43M (0.30% of total loans), and noninterest expenses rose 36% to $470M driven by $73M acquisition/integration costs.

• ·Common equity Tier 1 capital ratio for Mechanics Bancorp: 14.09% (newly reported post-merger)
• ·Tangible common equity ratio declined to 8.48% from 9.10%
• ·Loans to deposits ratio increased to 74.52% from 69.17%
• ·Full time equivalent employees grew 34% to 1,921

17-03-2026

Cortigent, Inc. (CRGT), a spin-off from Vivani Medical, Inc., is filing Amendment No. 17 to its S-1 for a firm commitment IPO of 1,500,000 shares of common stock at an anticipated $10.00 per share, with an underwriter option for 225,000 additional shares; post-IPO, Vivani will own approximately 77% of voting power, making Cortigent a controlled company. The company develops investigational brain implant devices including the Orion Visual Prosthesis (targeting $4B US TAM for 82,000 profoundly blind Americans) and Stroke Recovery System ($6B annual US TAM amid 610,000 annual strokes), building on the discontinued Argus II system. As an emerging growth company with no established public market and high investment risks, including FDA approval uncertainties for its products, the offering highlights promising markets but pre-commercial status.

• ·Argus II sales discontinued in 2019 to refocus on Orion
• ·Orion completed 6-year Early Feasibility Study in March 2025 with FDA Breakthrough Device designation
• ·Applied for NYSE American listing under symbol CRGT; offering will not proceed without approval
• ·Emerging growth company and smaller reporting company status
• ·Investigational devices (Orion and Stroke Recovery) require FDA approval; no assurance of success

17-03-2026

Delta Air Lines, Inc. executives are presenting at the J.P. Morgan Industrials Conference on March 17, 2026, at 7:30 a.m. ET. The presentation materials are furnished as Exhibit 99.1 under Item 7.01 and are not deemed 'filed' for liability purposes. The filing is signed by Daniel C. Janki, Executive Vice President & Chief Financial Officer.

• ·Presentation scheduled for 7:30 a.m. ET on March 17, 2026
• ·Information furnished under Item 7.01 is not deemed 'filed' per General Instruction B.2

17-03-2026

M3-Brigade Acquisition VI Corp., a SPAC formed on June 5, 2025, reported net income of $4.15M for the period ended December 31, 2025, driven by $4.61M in interest income on Investments held in Trust Account totaling $349.6M. However, the company recorded an operating loss of $0.43M from general and administrative costs and a shareholders' deficit of $15.56M primarily due to accretion of Class A ordinary shares subject to redemption. Total assets were $350.8M, including $0.88M in cash, with $34.5M Class A shares at $10.13 redemption value and deferred underwriting fees of $16.4M.

• ·Inception date: June 5, 2025
• ·Balance sheet date: December 31, 2025
• ·Filing date: March 17, 2026
• ·Class A redemption value: $10.13 per share
• ·Net income per share: $0.14 (basic and diluted for both Class A and B)
• ·Auditor: Independent Registered Public Accounting Firm (PCAOB ID: 100)

17-03-2026

AlphaTime Acquisition Corp, a blank check company, is seeking shareholder approval at its March 27, 2026 extraordinary general meeting to extend its business combination deadline from April 4, 2026 to December 4, 2026 via eight one-month extensions, each requiring a $15,000 trust deposit. While the latest extension meeting in December 2025 saw minimal redemptions of only 69 shares ($854), prior meetings resulted in heavy redemptions that reduced the trust account from $70.2M post-IPO to $4.8M currently and outstanding shares from over 6.4M to 2.17M. A January 2024 business combination agreement with HCYC Group remains unconsummated with no guarantees of completion.

• ·Extraordinary general meeting scheduled for March 27, 2026 at 9:00 a.m. ET.
• ·Initial IPO effective December 30, 2022; consummated January 4, 2023.
• ·Business combination agreement signed January 5, 2024, but no guarantee of closing.
• ·Transaction costs for IPO totaled $4,892,699.

17-03-2026

Bank7 Corp. reported total assets of $1.82B for 2025, up from $1.72B in 2024 and $1.69B in 2023, with average loans growing 6.6% YoY to $1.48B and net interest income increasing 1.9% to $87.9M; however, net interest margin declined to 4.94% from 5.11%, loan yields dropped to 7.92% from 8.56%, loan interest income fell 1.6% to $117.5M, and total noninterest income decreased 24.4% to $8.5M primarily due to lower oil and gas-related income. Noninterest-bearing deposits declined to $318M from $382M YoY and $434M in 2023, while shareholders' equity grew to $233M.

• ·Equity compensation plans approved by shareholders: 317,046 outstanding options at weighted average exercise price of $16.96, with 623,504 securities remaining available.
• ·Short-term investments average yield declined to 4.21% in 2025 from 5.04% in 2024.
• ·Taxable debt securities average balance dropped to $46.6M in 2025 from $90.2M in 2024.

17-03-2026

United Security Bancshares (UBFO) and Community West Bancshares (CWBC) announced on March 16, 2026, the receipt of regulatory approvals from the FDIC, California Department of Financial Protection and Innovation, and a waiver from the Federal Reserve Bank of San Francisco for their proposed merger, including the merger of UBFO's bank subsidiary into CWBC's. Shareholder approval meetings for both companies are scheduled for March 30, 2026, with closing expected in Q2 2026 subject to approvals and customary conditions. The announcement highlights forward-looking risks such as integration challenges, shareholder approval failures, and potential delays or non-completion.

• ·Press release attached as Exhibit 99.1
• ·CWBC filed Form S-4 registration statement including joint proxy statement/prospectus
• ·Refer to 10-K for Dec 31, 2024 (UBFO) and Dec 31, 2025 (CWBC) for risks

17-03-2026

Core Laboratories Inc. filed an 8-K/A on March 17, 2026, amending its February 4, 2026 earnings release for Q4 and FY ended December 31, 2025, to correct an understated income tax expense of $4.2 million, reducing net income by the same amount and diluted EPS by $0.09 per share. The adjustment arises from tax reconciliations, including deferred tax items related to insurance proceeds from an Aberdeen, U.K. facility fire, with additional prior period corrections such as a $5.6 million write-off of unrecoverable tax receivables and a $4.7 million misclassification. No changes to revenue, operating income, income before tax, or cash from operations.

• ·Form 10-K expected to be filed on or around March 17, 2026
• ·Adjustments are non-cash and do not impact net cash provided by operating activities

17-03-2026

On March 16, 2026, Community West Bancshares (CWBC) and United Security Bancshares (USB) announced receipt of regulatory approvals from the FDIC, California Department of Financial Protection and Innovation, and a waiver from the Federal Reserve Bank of San Francisco for their previously announced merger, including the merger of USB's bank subsidiary into CWBC's. Shareholder approval meetings for both companies are scheduled for March 30, 2026, with closing expected in Q2 2026 subject to approvals and customary conditions. While this advances the transaction, risks include potential shareholder rejection, integration delays, and dilution from new share issuance.

• ·Regulatory approvals from FDIC and California DFPI
• ·Waiver from Federal Reserve Bank of San Francisco
• ·Joint proxy statement/prospectus available on SEC website and company IR sites

17-03-2026

Baidu's revenue declined 3% YoY to RMB 129,079 million ($18.5B) in 2025 from RMB 133,125 million in 2024, continuing a trend of flat to negative growth after peaking at RMB 134,598 million in 2023. Operating income swung to a loss of RMB 5,823 million due to a RMB 16,190 million ($2.3B) impairment of long-lived assets, while net income attributable to Baidu plunged 76% YoY to RMB 5,589 million ($799M). However, total assets grew 5% to RMB 449,157 million ($64.2B) and Baidu shareholders' equity edged up 1% to RMB 266,330 million ($38.1B).

• ·Operating cash flow turned negative at RMB (3,013) million ($431M) in 2025, down from RMB 21,234 million in 2024.
• ·Cash used in investing activities increased to RMB 25,136 million ($3.6B) in 2025.
• ·Notes payable rose to RMB 51,021 million ($7.3B) as of Dec 31, 2025 from RMB 27,996 million in 2024.
• ·Short-term investments declined to RMB 90,661 million ($13.0B) as of Dec 31, 2025 from RMB 102,608 million in 2024.

17-03-2026

Urban One, Inc. reported Q4 2025 net revenue of $97.8M, down 16.5% YoY from $117.1M, with operating loss widening to $54.0M from $1.9M, net loss of $54.4M or $(12.24) per share versus $35.7M or $(7.81), and Adjusted EBITDA falling 38.3% to $15.6M from $26.9M amid weak cable TV delivery (-20% QoQ) and soft radio markets. Full-year 2025 revenue declined to $374.4M from $449.7M, though Adjusted EBITDA of $56.7M met guidance; positively, the company completed a debt exchange on Dec 18, 2025, repurchasing $185.0M of 2028 Notes for $111.0M cash plus $1.1M fee, issuing $60.6M 2030 First Lien Notes and $291.0M 2031 Second Lien Notes, and amending its ABL facility to $75.0M plus $25.0M incremental capacity.

• ·Q4 Radio Broadcasting Adjusted EBITDA $8.7M, down from $15.6M YoY; Cable Television $1.8M, down from $14.5M.
• ·FY 2025 Reach Media Adjusted EBITDA $(1.6M), down from $11.6M.
• ·Dec 31, 2025 total assets $593.0M vs $944.8M at Dec 31, 2024; stockholders' equity $24.6M vs $170.9M.
• ·Impairment of goodwill and intangibles $55.3M in Q4 2025.
• ·Nasdaq compliance regained in January 2026 via reverse stock split effective Jan 22, 2026.

17-03-2026

X4 Pharmaceuticals reported revenue of $35.1M for 2025, a massive increase from $2.6M in 2024 driven by $28.6M in new license revenue and product revenue growth to $6.5M. However, net loss widened to $79.2M from $37.5M due to the absence of a $105M gain on sale of a non-financial asset in 2024 and higher total operating expenses of $122M, despite reductions in R&D (-11%) and G&A (-29%). Cash and equivalents rose to $217.9M from $56.5M, supported by $238.6M in financing activities, though operating cash use was $85.6M.

• ·Common shares outstanding increased to 90.9M from 5.7M, indicating significant dilution.
• ·Long-term debt stable at approximately $76M.
• ·Warrant liability decreased to $1.0M from $13.8M.
• ·Net loss per share improved to $(1.87) from $(5.59) due to higher share count.
• ·Total stockholders’ equity rose to $186.3M from $22.1M.

17-03-2026

Pharma-Bio Serv, Inc. (PBSV) reported Q1 FY2026 revenues of $2.3M, down 7% YoY from $2.5M, with gross profit declining 6% to $722k amid higher cost efficiencies, while operating loss widened slightly to $95k. However, net income improved significantly to $33k from $9k YoY, driven by 29% higher other income, though a $1.7M dividend payout reduced retained earnings. Cash and equivalents rose 71% QoQ to $5.8M, supported by $2.8M in investing inflows from marketable securities.

• ·Operating cash flow used $390k in Q1 FY2026, improved from $429k YoY.
• ·Marketable securities decreased to $4.8M from $7.5M QoQ.
• ·Treasury stock repurchased: 3,100 shares for $1,681.
• ·Dividend: $0.075 per common share.

17-03-2026

Boise Cascade Co (BCC) filed a DEFA14A proxy statement ahead of its upcoming shareholder meeting, seeking election of 10 director nominees including Steven Cooper and Sue Taylor, with the Board recommending FOR all. Additional items include an advisory vote on the frequency of future executive compensation votes (Board recommends 1 Year), advisory approval of executive compensation (FOR), and ratification of KPMG as external auditors for the year ending December 31, 2026 (FOR). Shareholders can request proxy materials by April 16, 2026, via www.ProxyVote.com, phone, or email.

• ·Proxy materials request deadline: April 16, 2026
• ·KPMG auditors ratification for year ending December 31, 2026
• ·Contact options for materials: www.ProxyVote.com, 1-800-579-1639, sendmaterial@proxyvote.com (include control number)

17-03-2026

Hinge Health, Inc. appointed Tyler Sloat as a Class I Director effective March 16, 2026, with his term expiring at the 2026 annual stockholder meeting; he was also appointed Chair of the Compensation Committee and a member of the Audit Committee. Mr. Sloat, current COO of Freshworks Inc. (since August 2024) and former CFO of Zuora Inc. (2010-2020), will receive standard non-employee director compensation including an initial $400,000 RSU award vesting over three years and pro-rated annual cash fees of $65,000 (elected as RSUs). No arrangements, family relationships, or related-party transactions were disclosed.

• ·Mr. Sloat holds a B.A. in Economics from Boston College and an M.B.A. from Stanford University Graduate School of Business; registered (inactive) CPA in California.
• ·RSUs vest annually over three years or in full upon Change in Control, subject to continued service.
• ·Standard indemnification agreement to be entered with Mr. Sloat.

17-03-2026

IZEA Worldwide, Inc. reported revenue of $31.2M for the year ended December 31, 2025, down 13% from $35.9M in 2024, reflecting declines across segments amid cost-cutting efforts. However, total costs and expenses fell 40% to $33.1M, driven by sharp reductions in sales and marketing (-64%), general and administrative (-29%), and elimination of impairment expense, resulting in a modest net income of $42K versus a $18.9M loss and positive Adjusted EBITDA of $0.7M (2.1% margin) from -$11.1M. Cash from operating activities swung to $2.4M from -$11.5M, increasing cash to $50.9M, though total assets decreased to $57.5M from $62.2M.

• ·Basic and diluted income (loss) per common share: $0.00 (2025) vs $(1.10) (2024)
• ·Accounts receivable, net: $3.4M (Dec 31, 2025) vs $7.8M (Dec 31, 2024)
• ·Total current liabilities: $8.6M (Dec 31, 2025) vs $13.4M (Dec 31, 2024)
• ·Accumulated deficit: $(104.3M) (Dec 31, 2025) vs $(104.3M) (Dec 31, 2024), nearly flat
• ·Auditor: Grant Thornton LLP (PCAOB ID 248)

17-03-2026

This DEFA14A filing supplements the March 12, 2026 proxy statement for Texas Capital Bancshares, Inc.'s annual meeting on April 21, 2026, solely to clarify broker non-vote effects on proposals. Proposal 2 (ratification of Ernst & Young LLP as auditors for 2026) is routine, permitting broker discretion, while Proposal 4 (redomestication from Delaware to Texas) is non-routine, treating broker non-votes as votes against; no other changes are made. The update replaces a voting table on page 133 without altering voting instructions or proxy cards.

• ·Proposal 1: Election of Directors (plurality standard, non-routine).
• ·Proposal 3: Advisory vote on executive compensation (majority of shares present and entitled to vote, non-routine).
• ·Proposal 5: Advisory approval of increasing stockholder proposal threshold (majority of shares present and entitled to vote, non-routine).
• ·Proposal 6: Adjournment (majority of shares present and entitled to vote, routine).

17-03-2026

SafeSpace Global Corp reported no revenue for both the three and six months ended January 31, 2026, with net losses of $1.12M (3M, improved 11% YoY) and $2.74M (6M, worsened 41% YoY), driven by higher operating expenses including $2.85M total (up 49% YoY for 6M). Cash and equivalents declined 49% to $3.86M, with $2.45M used in operations and $1.24M in investing activities, while total assets and equity fell 29% each to $5.65M and $5.33M. Shares outstanding increased to 189.3M from 185.5M at period-end.

• ·Property and equipment, net increased to $427,761 from $0.
• ·Intangibles, net $1.26M as of Jan 31, 2026 (includes $1.22M in-process).
• ·Stock-based compensation $503K for six months ended Jan 31, 2026 (down from $881K YoY).
• ·Interest income $109K for six months ended Jan 31, 2026.

17-03-2026

Drugs Made In America Acquisition II Corp. (DMIIU), a SPAC listed on NASDAQ, entered into a non-binding Letter of Intent (LOI) effective March 5, 2026, with Alpha Multi Family Office (Investor) and S.E.E. Capital Partners Ltd. (Transaction Advisor) for a proposed $1.5M Senior Convertible Note to provide bridge financing for operational expenses and pursuit of a business combination. The funds will be held in escrow and convertible into discounted preferred equity upon events like execution or closing of a business combination agreement. No definitive agreements have been executed yet, and the LOI includes exclusivity for negotiations.

• ·LOI governed by laws of the State of Israel with exclusive jurisdiction in Tel Aviv courts.
• ·Conversion triggers include execution of definitive business combination agreement, closing of business combination, or restructuring of sponsor/capital structure.
• ·In case of no business combination, note subject to repayment or alternative consideration per definitive agreements.
• ·SEC 8-K filed March 17, 2026, covering Items 1.01, 2.03, 8.01, 9.01.

17-03-2026

Genius Sports Ltd reported FY2025 revenue of $669.5M, up 31% YoY from $510.9M, with strong growth in Betting Technology (33% to $471.5M) and Media Technology (37% to $144.5M), while Sports Technology grew modestly 5% to $53.5M. However, net loss widened to $111.6M from $63.0M due to operating expenses surging 63% to $305.2M, driven by general and administrative costs (+69%) and stock-based compensation (+188% to $160.5M), resulting in an operating loss of $151.3M versus $58.5M prior year. Adjusted EBITDA improved 59% to $136.2M, total assets reached $1.13B (up 43%), and cash equivalents rose to $280.6M.

• ·Operating cash flow increased slightly to $86.4M in FY2025 from $81.9M.
• ·Net cash used in investing activities widened to $92.9M from $62.7M.
• ·Net cash from financing activities was $144.0M, versus outflow of $7.6M prior year.
• ·Comprehensive loss was $140.5M in FY2025 versus $54.6M in FY2024.
• ·Diluted loss per share was $0.44 in FY2025 versus $0.27 in FY2024.

17-03-2026

Farmers National Banc Corp. filed Amendment No. 1 to its Form 10-K for the fiscal year ended December 31, 2025, solely to include Exhibit 97.1, the Policy relating to recovery of erroneously awarded compensation; no changes were made to financial statements or other information from the original filing on March 5, 2026. The filing reiterates key details such as the $498.8M market value of non-affiliate common shares as of June 30, 2025, and 37,672,309 shares outstanding as of February 20, 2026. This is an administrative update with no new financial metrics or period-over-period comparisons.

• ·Original 10-K filed March 5, 2026
• ·Amendment filed March 17, 2026
• ·Auditor: Crowe LLP (Columbus, OH)
• ·Agreement and Plan of Merger with Middlefield Banc Corp. dated October 22, 2025 (Exhibit 2.1)

17-03-2026

Andersen Group Inc. reported record FY2025 revenue of $838.7M, up 14.6% YoY from $731.6M in 2024, with Q4 revenue reaching $170.3M, a 19.6% YoY increase from $142.4M. However, GAAP net loss widened to $130.2M from $134.8M net income in 2024 due to IPO-related equity restructuring and compensation costs; adjusted net income improved to $217M and adjusted EBITDA to $226.3M. 2026 guidance forecasts revenue of $955-970M (14-15% growth) and adjusted EBITDA of $213-220M (22-23% margins), but anticipates a net loss from strategic investments.

• ·Private Client Services revenue share increased to 51.5% in FY2025 from 49.8% in FY2024, while Business Tax Services declined to 34.8% from 35.7% and Alternative Investment Funds to 8.7% from 9.5%.
• ·West region revenue share decreased to 42.1% in FY2025 from 44.3% in FY2024.
• ·Client engagements grew 10.6% to 22,450 in FY2025.
• ·Attrition rate slightly increased to 14.2% in FY2025 from 14.1% in FY2024.
• ·Top 10 client groups accounted for 5.5% of FY2025 revenue, up slightly from 5.0% in FY2024.
• ·IPO on Dec 18, 2025: 12,650,000 Class A shares at $16.00/share.

17-03-2026

Urgent.ly Inc. failed to regain compliance with Nasdaq Listing Rule 5550(b) by the March 16, 2026 deadline due to insufficient net income, resulting in trading suspension of its common stock (ULY) at the open on March 18, 2026, and delisting effective 10 days after Nasdaq files Form 25. However, the company entered a Merger Agreement with Agero, Inc. on March 13, 2026, involving a cash tender offer, and plans to transition trading to OTCQB Venture Market, though with no assurance of volumes or prices. The delisting is not expected to impact business operations, and the company will remain a reporting entity under the Exchange Act until the merger closes.

• ·Nasdaq notified of noncompliance previously; appeal hearing stayed delisting until March 16, 2026 compliance deadline.
• ·Company confirmed Merger Agreement to Nasdaq on March 16, 2026, but did not regain compliance.
• ·Tender offer by Agero not yet commenced; Schedule TO and 14D-9 to be filed with SEC.
• ·References prior SEC filings: Form 10-K for FY ended Dec 31, 2024 (filed Mar 14, 2025, amended Apr 17, 2025).

17-03-2026

Net sales rose 2.0% YoY to $6.05B for FY ended January 31, 2026, with growth across all segments: Outdoors (+1.2%), Sports & Recreation (+3.6%), Apparel (+2.4%), and Footwear (+1.2%); gross margin expanded 4.7% to 34.8%. However, SG&A expenses increased 8.2% to 26.3% of sales, causing operating income to decline 4.9% to $512.2M and net income to fall 10.0% YoY to $376.8M. Adjusted EBITDA decreased to $666.3M from $720.2M.

• ·Adjusted Net Income FY26: $393.2M (down from $439.5M FY25)
• ·Adjusted diluted EPS FY26: $5.78 (down from $6.02 FY25)
• ·Net cash provided by operating activities FY26: $434.8M (down 17.7% YoY)
• ·Adjusted Free Cash Flow FY26: $262.8M (down from $342.0M FY25)
• ·Dividends paid quarterly at $0.13 per share, total $34.7M
• ·Capital expenditures FY26: $212.7M, including $119.9M for new stores

17-03-2026

Longeveron Inc. reported revenues of $1.2M for the year ended December 31, 2025, down 50% YoY from $2.4M due to declines across clinical trial revenue (down 32% to $0.95M), contract manufacturing lease revenue (down 95% to $23K), and contract manufacturing revenue (down 54% to $222K). Net loss widened 42% to $22.7M from $15.9M, driven by R&D expenses surging 48% to $12.0M and G&A up 17% to $12.0M, while cash and equivalents dropped 76% to $4.7M amid $18.6M operating cash burn (up 34% YoY). However, net loss per share improved to $(1.29) from $(2.62), reflecting increased weighted average shares outstanding to 17.6M from 9.4M.

• ·Clinical trial expenses within R&D: $1.8M in 2025 (down from $2.0M), but CMC up to $1.7M from $0.3M and employee compensation up to $5.9M from $3.6M.
• ·Net cash provided by financing activities: $4.7M in 2025 vs $28.8M in 2024.
• ·Total assets declined to $10.3M from $25.6M; property and equipment net down to $1.8M from $2.4M.
• ·Basic and diluted net loss per share: $(1.29) in 2025 vs $(2.62) in 2024.

17-03-2026

Hilton Grand Vacations Inc. (HGV) filed a DEFA14A Definitive Additional Proxy Materials on March 17, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No substantive financial or operational details are provided in the filing header.

17-03-2026

Vesta Real Estate reported rental revenue growth of 12.4% YoY to $283.2M for FY 2025, with portfolio expansion to 231 properties (+3.1% YoY) and GLA of 42.95M sq ft (+6.5% YoY); Adjusted NOI rose 12.1% YoY to $259.4M and profit increased 8.3% to $241.9M. However, stabilized occupancy declined to 93.6% (-2.0% YoY), number of tenants fell 5.7% to 181, management fees dropped to $0, and gain on property revaluation sharply decreased to $52.1M from $270.7M.

• ·Automotive industry contributed 25.7% of total rental income ($72.69M).
• ·Querétaro region: 16.68% of total GLA, 11.0% of rental income.
• ·Estado México region generated 17.8% of rental income despite 11.28% GLA share.
• ·Management fees declined to $0 in FY2025 from $0.4M in FY2024.
• ·Basic EPS: $0.2850 FY2025 vs $0.2563 FY2024 (+11.2%).
• ·Vesta FFO: $175.0M FY2025 (+9.2% YoY) or $0.2032 per share.
• ·Total expected investment in Bajio projects: $59.0M, expected completion Oct-26 to Aug-26.

17-03-2026

Revenue for the year ended December 31, 2025 surged 2050% to $23.6 million from $1.1 million in 2024, driven by the Acquisition, while Q4 2025 revenue increased 2092% YoY to $6.1 million but declined 1.7% sequentially from Q3. Operating loss from continuing operations narrowed to $4.7 million for FY 2025 (from $5.1 million) and net loss decreased 77% to $2.0 million (from $8.4 million), with positive Adjusted EBITDA of $5 thousand in Q4, though FY Adjusted EBITDA was negative $1.1 million and litigation expenses totaled $0.7 million.

• ·Cash provided by operations was $0.1 million for Q4 2025 vs cash used of $1.5 million in Q4 2024.
• ·No long-term debt at Dec 31, 2025.
• ·Net loss Q4 2025 improved 41% vs previous quarter.

17-03-2026

Phoenix Energy One, LLC reported total revenues of $687.2M for 2025, up 144.4% YoY from $281.2M, driven by product sales surging 248.1% to $437.4M and new purchased crude oil sales of $113.4M; however, mineral and royalty revenues declined 18.3% to $125.0M. Production across all properties more than doubled to 9.9M Boe (avg daily 27,190 Boe/d), but realized prices fell with oil at $62.45/Bbl (down 8.8% YoY) and higher unit operating costs of $19.00/Boe (up 17.9%). Net income swung to $66.1M from a $24.8M loss, with total proved PV-10 reserves value rising 66.7% to $1.78B.

• ·2026 guidance: Production 15.5-16.8M Boe (avg daily 42k-46k Boe/d); EBITDA $475-605M.
• ·Bakken oil production 7.83M Bbl in 2025 (up 159% YoY from 3.02M Bbl).
• ·Segment operating profit: Operating $165.0M (up from $44.1M), Mineral/Non-op $27.0M (down from $43.5M).

17-03-2026

On March 13, 2026, Jaisim Shah retired as CEO, President, and Director of Semnur Pharmaceuticals, Inc., resulting in the board size decreasing from six to five members, with no disagreements on company matters. Henry Ji, Ph.D., previously Executive Chairperson, was immediately appointed as new CEO and President, while Stephen Ma, former CFO, was named COO effective March 17, 2026, with no changes to their compensation. Shah received a separation agreement providing six months of base salary continuation at a $1.25M annual rate.

• ·Shah granted 90-day extension to exercise vested stock options.
• ·No family relationships or disclosable related party transactions under Item 404(a) for Ji or Ma beyond Scilex ties.
• ·Company is an emerging growth company trading on OTCQB.

17-03-2026

Global Payments Inc. (GPN) issued Definitive Additional Proxy Materials (DEFA14A) for its 2026 Annual Shareholder Meeting on April 30, 2026, at 9:00 AM EDT virtually. Key proposals include the election of 12 director nominees (board recommends FOR all), advisory approval of 2025 named executive officer compensation (FOR), ratification of Deloitte & Touche LLP as independent auditors for the year ending December 31, 2026 (FOR), and a shareholder proposal on the right to act by written consent (AGAINST). Proxy materials and the 2025 Annual Report are available online at www.ProxyVote.com, with requests for paper/email copies due by April 16, 2026, and voting deadline of April 29, 2026, 11:59 PM ET.

• ·Meeting held virtually at www.virtualshareholdermeeting.com/GPN2026Vote
• ·Company address: 3550 Lenox Road, Suite 3000, Atlanta, GA 30326
• ·Request materials via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com (include control number)

17-03-2026

On March 11, 2026, Suzanne Seandel notified 8x8, Inc. of her resignation as Chief Accounting Officer and principal accounting officer, effective at a mutually agreeable date expected in mid-April 2026, not due to any disagreement with company operations, policies, or practices. The company plans a consulting arrangement with Ms. Seandel through May 31, 2026, and has commenced a search for her successor. Effective the separation date, Kevin Kraus, the current Chief Financial Officer, will be appointed principal accounting officer with no new compensatory agreements.

• ·Kevin Kraus, age 56, was appointed permanent CFO on June 5, 2023, after serving as Interim CFO from November 2022 to June 2023 and SVP of Finance since October 2019.
• ·Prior to 8x8, Kevin Kraus was VP of Finance at Imperva (2018-2019) and Senior Director of Finance at Gigamon (2015-2017).
• ·Mr. Kraus holds a bachelor’s degree in accounting from Rutgers University and an MBA from Pennsylvania State University.
• ·No family relationships or material conflicts of interest for Mr. Kraus.

17-03-2026

Kevin A. Lobo notified Parker-Hannifin Corporation on March 13, 2026, that he will not stand for reelection to the Board of Directors at the 2026 Annual Meeting of Shareholders due to his election to the Board of GE HealthCare Technologies Inc. Mr. Lobo, who has served as a director since 2013, stated that his decision was not due to any disagreement with the company's operations, policies, or practices. He is expected to continue serving until the expiration of his current term.

• ·Filing signed by Joseph R. Leonti on March 17, 2026

17-03-2026

Ingevity Corporation (NGVT) issued definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting on April 29, 2026, at 9:30 AM ET virtually, with voting deadline April 28, 2026. Proposals include election of nine director nominees, advisory vote on Named Executive Officer compensation (Say-on-Pay), ratification of PricewaterhouseCoopers LLP as independent auditors for 2026, and amendment to increase authorized shares under the 2025 Omnibus Incentive Plan. Shareholders can access materials online at www.ProxyVote.com or request paper copies by April 8, 2026.

• ·Proxy materials available at www.ProxyVote.com or www.virtualshareholdermeeting.com/NGVT2026
• ·Material request deadline: April 8, 2026
• ·Control numbers referenced: V85511-P45803, V85512-P45803

17-03-2026

Ball Corporation's 2026 Proxy Statement highlights record 2025 performance including $13.16B in consolidated net sales, record EVA dollars, adjusted free cash flow, and diluted EPS, driven by operational improvements, volume growth, and significant share repurchases. The Board proposes electing nine director nominees (eight independent), ratifying PricewaterhouseCoopers LLP as auditor, approving executive compensation on an advisory basis, and amending the 2013 Stock and Cash Incentive Plan. Strong governance features include an independent Chairman, diverse board composition (3/9 women, 2/9 ethnically diverse), and robust sustainability initiatives.

• ·Board held 6 meetings in 2025; committees: Audit (5), Finance (4), Human Resources (6), Nominating/Corporate Governance (4); total 25.
• ·3 new directors added in past 5 years.
• ·Director skills: 9 with executive leadership and operations/strategy, 8 with global business experience.

17-03-2026

Traeger, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, approved by the Board and stockholders, to implement a 1-for-50 reverse stock split of its Common Stock effective at 5 p.m. ET on March 17, 2026. No fractional shares will be issued; holders will receive cash payments based on the NYSE closing price adjusted for the split. The amendment authorizes 1,000,000,000 shares of Common Stock and 25,000,000 shares of Preferred Stock, with par value remaining at $0.0001 per share.

• ·Reverse stock split reclassifies every 50 shares of Common Stock into 1 share.
• ·Fractional share cash payments determined based on total shares represented by surrendered certificates or book-entry positions.

17-03-2026

Janus Henderson Group plc filed this DEFA14A additional proxy statement on March 17, 2026, in connection with a proposed transaction, referencing the definitive proxy statement filed March 11, 2026 (mailed March 12, 2026) and Schedule 13E-3. The filing urges shareholders to review these documents for key details on the transaction and discloses participants in the proxy solicitation, including directors and executives. As of December 31, 2025, Janus Henderson managed $493B in assets under management with over 2,000 employees across 25 cities worldwide.

• ·Definitive proxy statement filed March 11, 2026; Schedule 13E-3 filed same date.
• ·Annual Meeting Proxy Statement filed March 21, 2025.
• ·Headquartered in London; listed on NYSE.

17-03-2026

Fulgent Genetics, Inc. (NASDAQ: FLGT) completed the acquisition of certain assets of Bako Diagnostics and StrataDx for a total combined purchase price of approximately $56.9 million in cash, subject to post-closing adjustments, as previously announced on December 22, 2025. The deal expands Fulgent's laboratory services into specialty pathology and dermatopathology. While no immediate financial impacts are quantified, forward-looking statements note potential integration risks and challenges in realizing benefits.

• ·Acquisition previously announced on December 22, 2025.
• ·Piper Sandler & Co. acted as exclusive financial advisor and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. as legal counsel to Fulgent.
• ·EV Health Partners acted as exclusive financial advisor and Latham & Watkins LLP as legal counsel to Consonance Capital Partners, Bako Diagnostics, and StrataDx.
• ·Fulgent's Form 10-K for fiscal year ended December 31, 2025, filed February 27, 2026.

17-03-2026

Herbalife Ltd. issued definitive additional proxy materials for its 2026 Annual Meeting scheduled for April 30, 2026, at 8:30 AM PDT in Los Angeles, CA, with virtual attendance available. Key proposals include the election of 11 director nominees, an advisory vote to approve named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditors for fiscal year 2026; the board recommends voting 'For' all items. No financial performance metrics or period comparisons are disclosed in this filing.

• ·Vote deadline: April 29, 2026, 11:59 PM ET
• ·Proxy materials request deadline: April 05, 2026
• ·Meeting address: 800 W. Olympic Blvd. Suite 406, Los Angeles, CA 90015
• ·Virtual meeting link: meetnow.global/MMVF2KX
• ·Fiscal year end: December 31
• ·NYSE broker discretionary voting applies to routine matters if instructions not received 10 days prior

17-03-2026

Alexander & Baldwin, Inc. (ALEX) has been taken private through the completion of an acquisition by a joint venture formed by MW Group, Blackstone Real Estate, and DivcoWest, valued at approximately $2.3 billion enterprise value including debt. Shareholders received $21.20 per share in cash, net of a $0.35 Q4 2025 dividend (resulting in $20.85 net), following approval at a special meeting on March 9, 2026. A&B's common stock has ceased trading on the NYSE and the company is now privately held.

• ·Transaction initially announced on December 8, 2025
• ·Shareholder approval at Special Meeting on March 9, 2026
• ·Q4 2025 dividend record date December 19, 2025; paid January 8, 2026
• ·A&B's 156-year history in Hawaiʻi real estate sectors including agricultural, transportation, tourism, construction, residential, and commercial

17-03-2026

On March 12, 2026, ImageneBio, Inc. (NASDAQ: IMA) announced a mutual separation from Erin Butler, Senior Vice President, Finance & Administration and Principal Accounting Officer, effective March 20, 2026, with severance benefits per her October 21, 2024 agreement. Effective the same date, the board appointed Bob Lally, current Senior Vice President, Finance & Operations, as the new Principal Accounting Officer. No new compensatory arrangements, family relationships, or disclosable transactions were noted for Mr. Lally.

• ·Bob Lally served as SVP Finance & Operations at Ikena Oncology from December 2022 to July 2025; VP Finance (Feb 2019-Mar 2021) and COO (Mar 2021-Jun 2022) at Prevail Therapeutics; Executive Director Finance and Controller at Arsanis from May 2016 to March 2019.
• ·Holds B.S. in finance from University of Massachusetts, Lowell.
• ·Separation Agreement to reference Severance Rights Agreement filed as Exhibit 10.16 to 8-K on July 29, 2025.

17-03-2026

On February 19, 2026, the Board of Directors of First Guaranty Bancshares, Inc. declared a quarterly cash dividend of $0.01 per share on its outstanding common stock, payable on March 31, 2026 to shareholders of record as of March 27, 2026. This announcement highlights the company's ongoing commitment to shareholders, marking the 131st consecutive quarterly dividend paid to common shareholders.

• ·Filing made pursuant to Item 8.01 Other Events.
• ·Registrant incorporated in Louisiana, IRS Employer ID 26-0513559, Nasdaq-listed.

17-03-2026

New Peoples Bankshares, Inc. announced on March 17, 2026, that its Board of Directors authorized the continuation of its share repurchase program, permitting the buyback of up to 500,000 shares through March 31, 2027. No financial performance metrics or declines were reported in the filing.

• ·Filing submitted under Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits)
• ·Press release attached as Exhibit 99.1